

Scientific Programme Schedule

The following scientific programme is correct at time of printing. Any update or amendment will be featured on the Final Programme and on the ESC Web Site www.escardio.org

SUNDAY 26 JUNE 2005 - AFTERNOON													
	AUDITORIUM	ROOM 2.A	ROOM 1.B	ROOM 1.A	ROOM 0.A	ROOM 3.A	ROOM 2.B	ROOM 2.C	POSTER AREA				
12:00 13:30	SATELLITE SYMPOSIA												
	COFFEE BREAK												
14:00	Evidence based electrical management in cardiology Chairpersons: E. Erdmann, C. Linde Congestive heart failure D. Gras Syncope R. Sutton Sudden death D. Boecker Atrial fibrillation H. Crijns	Cardiac memory: is it time to step out of the closet? Chairpersons: N.S. Peters, M. Franz Cardiac memory of what, why and how P. Bjerregaard Atrial memory in atrial fibrillation J.C. Geller Interaction between cardiac memory and anti arrhythmic drugs H.P. Plantikow Cardiac memory and hypertrophic cardiomyopathy L. Bergfeldt	The coronary sinus and the cardiac veins in implanting procedures Chairpersons: J.M. Almendral Garotte, S. Kacet Embryology and anatomy G. Thiene* Preprocedure assessment of venous anatomy M. Jongbloed LV lead placement guided by mechanical mapping G. Ansalone Handling technical problems during the procedure: tips and tricks M. Gasparini	Atrial remodelling in atrial fibrillation Chairpersons: A.A. Grace, A.S. Manolis Electric - structural - molecular: Who is the first? U. Schotten Endocrine function: action or reaction? M. Burnier Clinical consequences of remodelling: is it reversible? P. Attuel Causal therapy : ACE inhibitors, ARB, aldosterone antagonists A. Hernandez*	ORAL SESSIONS								
15:30	COFFEE BREAK												
15:45	Atrial fibrillation from mechanism to symptoms Chairpersons: J.Y. Le Heuzey, M. Trusz-Gluza Substrates and triggers M. Allessie* Haemodynamic impact of atrial fibrillation P. Vardas Where the symptoms come from? J.M. Davy Atrium, atrial appendix and thromboembolism C. Moro Serrano	Right ventricular pacing is obsolete Chairperson: C. Leclercq Pro: N. Sadoul* Con: F. Naccarella Drug treatment of NM syncope is: Chairperson: H. Ector Useful: A. Raviello Obsolete: A.G. Manolis	Sudden death and sport Chairpersons: F. Carré, J. Hoogsteen Screening and echocardiography abnormalities D. Corrado Sports and hypertrophic cardiomyopathy P.M. Elliott Sports and RVC G. Fontaine Sports and catecholaminergic polymorphic ventricular tachycardia A. Katz	Antithrombotic therapy in atrial fibrillation Chairpersons: F.W.A. Verheugt, E. Aliot Low molecular weight heparins? A. Cohen Ximelagatran: the Sportif trials. S.B. Olsson Clopidogrel: The Active trial C.A. Morillo Atrial appendage occluders H. Sievert	ORAL SESSIONS								
	COFFEE BREAK												
17:30 18:30	OPENING CEREMONY	Followed by the Opening Cocktail in the Exhibition Area											

* Still to be confirmed at the date of printing (09 February 2005).

MONDAY 27 JUNE 2005 - MORNING

	AUDITORIUM	ROOM 2.A	ROOM 1.B	ROOM 1.A	ROOM 0.A	ROOM 3.A	ROOM 2.B	ROOM 2.C	POSTER AREA
08:30	<p>Radiofrequency ablation of ventricular arrhythmias Chairpersons: R. Cappato, P.P. Adragao</p> <p>Ablation of idiopathic ventricular tachycardia A. Katsivas*</p> <p>Ablation of stable ventricular tachycardia P. Della Bella</p> <p>Ablation of unstable ventricular tachycardia A. Arenal-Maiz</p> <p>Ablation of ventricular fibrillation M. Haissaguerre*</p>	<p>Is beta blocker enough to prevent sudden death in patients with the long QT syndrome? Chairperson: P. Bjerregaard</p> <p>Beta blocker is enough - L. Jordaens Beta blocker is not enough - W. Schoels</p> <p>Non invasive assessment identifies post MI patients needing an implantable cardioverter-defibrillator Chairperson: A.N. Parkhomenko</p> <p>Pro - R. Pedretti Contra - G. Steinbeck</p>	<p>New developments in atrial fibrillation ablation. Joint session with the Asian Pacific Society of Pacing and Electrophysiology Chairpersons: M. Munawar, J. Brugada Terradellas</p> <p>Substrate modification produces enough electrophysiological changes to prevent atrial fibrillation - C. Papponne Strategy of catheter ablation for atrial fibrillation: insight from the trigger and substrate mapping - S.A. Chen Extensive electrical and anatomical mapping is mandatory to achieve a permanent effective result J. Perez Villacastin Pulmonary vein as the arrhythmogenic substrate of atrial fibrillation: study using a basket catheter - K. Kumagai</p>	<p>Technical progress: what do we have, what do we need? Chairpersons: K. Steinbach, W. Piwowarska</p> <p>Autocapture B. Brandts Multiprogrammability and automaticity D.J. Wright Antitachy therapies O. Oseroff* Lead technology C. Bucknall</p>	Award	ORAL SESSIONS			POSTER SESSION 1
10:00	COFFEE BREAK - MODERATED POSTERS SESSION								
11:00	<p>Honorary Lecture Chairpersons: L. Kappenberger, J. Brugada Terradellas, J. Kautzner</p> <p>Sudden death: fatality or destiny? P.J. Schwartz</p> <p>Electromechanical dissociation of the heart P. Brugada Terradellas</p> <p>Catheter ablation for arrhythmias: from AV nodal reentry to ventricular fibrillation M. Haissaguerre</p>	<p>Atrial fibrillation, the role of atrial- and ventricular resynchronisation therapy Chairpersons: I. Fernandez Lozano, P. Ritter</p> <p>The role of atrial synchronisation in cardiac resynchronisation therapy patients - M. Santini Value of cardiac resynchronisation therapy in atrial fibrillation patients M. Taborsky Rate or rhythm control in cardiac resynchronisation therapy patients N. Saoudi Positive effect of cardiac resynchronisation therapy on atrial fibrillation burden - J. Morgan</p>	<p>Atrial fibrillation: from channel to structure Chairpersons: D.E. Atsma, M.J. Janse</p> <p>Remodelling the Na K pump during atrial fibrillation K. Sipido* Specificity of left and right atrium D. Di Virtual atrium: a computer based model V. Jacquemet From the action potential to tissue activation: stretch and Ca waves A. Zaza*</p>	<p>Optimal lead positioning in cardiac resynchronisation therapy Chairpersons: M. Gasparini, J.L. Mont Girbau</p> <p>Optimal right ventricular lead position H.D. Gammage Optimal left ventricular lead position C. Alonso Optimal atrial lead position with regard to inter atrial conduction delay L. Padeletti Surgical approach for LV lead positioning A. Auricchio</p>	<p>Implanted devices and monitoring capacities: what do we learn? Chairpersons: A.P. Fitzpatrick, G. Theodorakis International study on syncope of uncertain etiology ISSUE 2 A. Moya i Mitjans Carisma H.V. Huikuri Syncope and falls in the elderly To be announced* Sleep apnea syndrome E. Simantirakis</p>	ORAL SESSIONS			POSTER SESSION 1
12:30	<p>Homolka hospital - Prague Live transmission 1 Chairperson: H. Kottkamp; G.Hindricks</p> <p>CT/MR image integration with electroanatomical mapping to guide catheter ablation of atrial fibrillation P. Neuzil, V. Reddy Cardiac surgery for atrial fibrillation in heart failure patient - the Maze procedure and left ventricular lead placement M. Taborsky, S. Cerny</p>	<p>How to ablate outflow tract tachycardias Chairperson: C. Blomström-Lundqvist</p> <p>M.J. Schaliij J. Neuzner</p>	<p>How to avoid and handle complications in atrial fibrillation interventions Chairperson: M. Haissaguerre*</p> <p>Speaker 1: A. Rossillo Speaker 2: R. Cihak</p>	<p>Implantation techniques in atrial fibrillation Chairperson: A. Lubinski</p> <p>Failure of coronary sinus approach V. Paul Coronary sinus dissection: is it an issue? P.P.H.M. Delnoy*</p>	<p>The surface echocardiography in atrial fibrillation / computer assisted echocardiography in atrial fibrillation Chairperson: I. Gussak</p> <p>The surface echo-cardiography in atrial fibrillation - A. Forclaz Computer assisted echocardiography in atrial fibrillation A. Van Oosterom</p>	<p>Experimental pacing Chairperson: D. Andresen</p> <p>Subthreshold pacing for heart failure To be announced Structural and metabolic changes induced by pacing E. Raddatz</p>	<p>How to select the optimal implantable cardioverter-defibrillator system for an individual patient Chairperson: R.N.W. Hauer</p> <p>Speaker 1: K. Adalet* Speaker 2: L. van Erven</p>		
13:30									

* Still to be confirmed at the date of printing (09 February 2005)

MONDAY 27 JUNE 2005 - AFTERNOON

	AUDITORIUM	ROOM 2.A	ROOM 1.B	ROOM 1.A	ROOM 0.A	ROOM 3.A	ROOM 2.B	ROOM 2.C	POSTER AREA
14:00	<p>Joint session with NASPE How to translate sudden cardiac death guidelines into daily clinical practice? Chairpersons: G. Hindriks, M. Cain</p> <p>Current status in Europe: still an individual decision making process? J. Camm</p> <p>Current status in the US: does the high implementation rate of implantable cardioverter-defibrillators versus Europe reflect the real need or is it overuse? J. Ruskin*</p> <p>Primary prevention with the implantable cardioverter-defibrillator in dilated cardiomyopathy: is it justified? M. Fromer</p> <p>Socio-economical aspects are only part of the story E. Erdmann</p>	<p>Atrial fibrillation - to cure or rate regulate Chairperson: C. Pappone</p> <p>Atrial fibrillation should primarily be cured M. Hocini</p> <p>Atrial fibrillation should only be rate regulated P. Blomström</p> <p>Every atrial fibrillation patient needs antithrombotic treatment Chairperson: S. Lévy</p> <p>Pro G.Y.H. Lip</p> <p>Con R. Willems</p>	<p>Management of cardiac resynchronisation therapy complications Chairpersons: V.M. Sanfins, J. Borbola</p> <p>Chronic coronary sinus obstruction: is it clinical problem? B. Lamp</p> <p>Left ventricular lead perforation A. Curnis</p> <p>Cardiac resynchronisation therapy related infections J.I. Garcia Bolao</p> <p>Left ventricular lead failure J.Kautzner</p>	<p>Programming and follow-up Chairpersons: M. Santini, J.L. Zamorano Gomez</p> <p>Optimal AV delay and heart rate P. Mabo</p> <p>Tools for optimising V-V delay F. Braunschweig</p> <p>Programming a pacemaker dependent patient W.G. de Voogt</p> <p>Optimal management of heart failure patients after cardiac resynchronisation therapy L. Gianfranchi</p>	<p>Cardiac stimulation in the XXIst century. Joint session with SOLAECE Chairpersons: O. Oseroff, P.E. Vardas</p> <p>Tricameral stimulation: is it going to be standard? J.L. Montenegro</p> <p>Do we need complex and long lasting PM in elderly? - A. Del Rosso</p> <p>Are we going to change the site of stimulation in the right ventricle? J.C. Pachon Mateos</p> <p>4 Haemodynamic sensors: are they finally ready? W. Jung</p>	ORAL SESSIONS			POSTER SESSION 2
15:30									
COFFEE BREAK - MODERATED POSTERS SESSION									
16:30	<p>Diagnosis and management of arrhythmias in genetically based diseases Chairpersons: R. Brugada, S. Priori</p> <p>Brugada syndrome P. Brugada Terradellas</p> <p>Long QT syndrome C. Napolitano</p> <p>Short QT Syndrome M. Borggrefe</p> <p>Cardiac conduction defects related to connexins and to SCN5A F. Charpentier</p>	<p>Cost of care in arrhythmias Chairpersons: L. Kappenberger, A.J. Camm</p> <p>The cost of stimulation for bradycardia H. Ector</p> <p>Cost effectiveness of ICD H.U. Klein</p> <p>The cost of cardiac resynchronisation therapy P. Ritter</p> <p>Cost of care repartition in atrial fibrillation S. Lönnerholm</p>	<p>Pacemaker lead extraction Chairpersons: M. Chauvin, J.I. Garcia Bolao</p> <p>Conventional techniques P. Neuzil</p> <p>Laser sheath for lead extraction M. Abecasis</p> <p>Electrosurgical sheath E. Rowland*</p> <p>Echo-assisted lead extraction M.G. Bongiorno</p>	<p>How new technologies modify catheter ablation procedures Chairpersons: D.W. Davies, N. Saoudi</p> <p>Intracardiac echo T. Szili-Torok</p> <p>Navigation systems D. Cavaco</p> <p>Joystick ablation S. Ernst</p> <p>New energies L.M. Rodriguez*</p>	<p>Mouse models of cardiac arrhythmias: what have we learned? Chairpersons: A.G. Kleber, M.A. Vos</p> <p>Long QT mouse models G. Koren</p> <p>Mouse models for SCN5A-linked congenital Lenegre disease - D. Escande</p> <p>The delta-KPQ-SCN5A mouse - E. Carmeliet</p> <p>Mouse models with connexin defects J.M.T DE Bakker</p>	ORAL SESSIONS			POSTER SESSION 2
18:00									
18:15	SATELLITE SYMPOSIA								
19:45									

* Still to be confirmed at the date of printing (09 February 2005)

TUESDAY 28 JUNE 2005 - MORNING

	AUDITORIUM	ROOM 2.A	ROOM 1.B	ROOM 1.A	ROOM 0.A	ROOM 3.A	ROOM 2.B	ROOM 2.C	POSTER AREA	
08:30	<p>Non-invasive imaging of dyssynchrony in cardiac resynchronisation therapy patients Joint Session with the Heart Failure Association Chairpersons: R. Sutton, F.J. Pinto</p> <p>Focus on V-V delay during follow-up O.A. Breithardt</p> <p>Septal to lateral delay: selection of patients - J.J. Bax</p> <p>Selection of patients with a narrow QRS complex based on asynchrony P. Sogaard</p> <p>Right ventricular imaging in heart-failure: right ventricular function after cardiac resynchronisation therapy and possible role of resynchronisation therapy in right heart failure - L. Pierard</p>	<p>In patients with post MI, preserved EF and monomorphic VT: Chairperson: B. Luderitz</p> <p>Catheter ablation alone is sufficient P. Loh</p> <p>An implantable cardioverter-defibrillator is needed S.H. Hohnloser</p> <p>Surgical VT ablation should be performed in all patients undergoing cardiac surgery Chairperson: R. Dion</p> <p>Pro - J. Bytesnik Contra - L. de Roy</p>	<p>Indication of implantable defibrillators in non ischaemic cardiomyopathies Chairpersons: M. Block, J. Brugada Terradellas</p> <p>Hypertrophic cardiomyopathies L.J. Monserrat Iglesias</p> <p>Right ventricular cardiomyopathy R. Frank</p> <p>Long and short QT syndromes E. Delacrétaz</p> <p>Brugada syndrome A. Leehnhardt</p>	<p>Optimal treatment modalities for atrial fibrillation Chairpersons: F. Gaita, P. Attuel</p> <p>The role of pulmonary vein electrical isolation P. Jais</p> <p>The role of substrate and vagal modification by catheter ablation C. Pappone</p> <p>Percutaneous epicardial catheter ablation M. Scanavacca</p> <p>When do we need the surgeon? F.J. Melo*</p>	ORAL SESSIONS				POSTER SESSION 3	
10:00										
COFFEE BREAK - MODERATED POSTERS SESSION										
11:00	<p>Update on Device trials Chairpersons: I.E. Ovsyshcher, P. Alboni</p> <p>Battery longevity A. Proclemer</p> <p>Lead survival M. Gammage</p> <p>Surgical complications A.S. Revishvili</p> <p>Infection S. Kacet</p>	<p>Quality standards of devices therapy Chairpersons: I.E. Ovsyshcher, P. Alboni</p> <p>Battery longevity A. Proclemer</p> <p>Lead survival M. Gammage</p> <p>Surgical complications A.S. Revishvili</p> <p>Infection S. Kacet</p>	<p>Diagnosis and risk stratification in Brugada syndrome Chairpersons: P. Brugada Terradellas, G. Fontaine</p> <p>Diagnostic criteria: is drug testing necessary? - H. Tan</p> <p>Genetic testing: is familial screening necessary? - S.G. Priori</p> <p>Risk stratification: is EP study necessary? - W. Grimm</p> <p>Treatment: is implantable cardioverter-defibrillator necessary? J. Brugada Terradellas</p>	<p>Syncope Chairpersons: A. Raviele, M. Brignole</p> <p>Mechanisms and prevalence of syncope E. Pruvot</p> <p>The syncope clinic A.P. Fitzpatrick</p> <p>Diagnostic tests for syncope P. Kulakowski</p> <p>Therapy J.-J. Blanc</p>	ORAL SESSIONS				POSTER SESSION 3	
12:30										
12:45	<p>IKEM - Intitute for clinical and experimental medicine - Prague Live transmission 2 Chairpersons: N. Marrouche, M. Morgan</p> <p>Catheter ablation of atrial fibrillation guided by intracardiac echocardiography A. Natale, R. Chak</p> <p>Left ventricular lead implant in heart failure patient P. Peichl, J. Kautzner</p>	<p>Electrical storms: how to manage Chairperson: J.J. Blanc</p> <p>Acute management. J. Farré</p> <p>Catheter ablation of medically refractory ventricular tachycardia P. Neuzil</p>	<p>How to use non invasive tests in risk stratification of sudden death in patients post MI Chairperson: G. Parati</p> <p>Holter and HRV H.V. Huikuri</p> <p>T-Wave alternans M.J.M. Oliveira*</p>	<p>Cardioversion Chairperson: D.V. Cokkinos</p> <p>Electrical or pharmacological CV S.B. Olsson</p> <p>Anticoagulation: when, what, how long? S. Lévy</p>	<p>Evaluation of neurally mediated syndromes. Chairperson: J. Mansourati</p> <p>Carotid sinus massage F. Ammirati</p> <p>Tilt test A. Garcia Alberola</p>	<p>Ablation of VT in ischaemic heart disease Chairperson: D. Lacroix</p> <p>Electrophysiologically guided J.M. Almendral</p> <p>Anatomically guided M. Kottkamp</p>	<p>Management of hypertrophic cardiomyopathy Chairperson: W.J. McKenna</p> <p>Anatomical approach H.J. Kuhn</p> <p>Electrical approach E. Aliot</p>	<p>Implantable cardioverter-defibrillator lead extraction Chairperson: J. Luki</p> <p>Speaker 1: F. Bracke</p> <p>Speaker 2: W. Kargul</p>		
13:30										

TUESDAY 28 JUNE 2005 - AFTERNOON

	AUDITORIUM	ROOM 2.A	ROOM 1.B	ROOM 1.A	ROOM 0.A	ROOM 3.A	ROOM 2.B	ROOM 2.C	POSTER AREA
14:00	<p>Atrial fibrillation from symptom to therapy Chairpersons: H. Crijns, S. Honhloser</p> <p>Symptoms are the tip of the iceberg N.M. van Hemel</p> <p>Quality of life in paroxysmal and chronic atrial fibrillation P. Dorian</p> <p>Economic aspects of atrial fibrillation J.Y. Le Heuzey</p> <p>Endpoint of AF: treatment G. Breithardt</p>	<p>Is the echocardiography still the gatekeeper for cardiac resynchronisation therapy implantation? Chairperson: J.J. Bax</p> <p>Protagonist: C. Linde Antagonist: C. Leclercq</p> <p>Should we implant a biventricular pacemaker in patients with mild left ventricular dysfunction and a bradycardia pacemaker indication? Chairperson: A. Auricchio</p> <p>Protagonist: E. de Teresa Galvan Antagonist: P. Geelen</p>	<p>Radiofrequency ablation in paediatric population Chairpersons: J. Hebe, N.M.S. De Groot</p> <p>Foetal and neonatal arrhythmias N. Blom</p> <p>Selection of candidates: the larger, the better J. Kugler</p> <p>Ablation of post-op atrial arrhythmias J.K. Friedman</p> <p>Ablation of post-op ventricular arrhythmias A. Kirstein Pedersen*</p>	<p>Atrial fibrillation and heart failure Chairpersons: P.E. Vardas, F. Garcia Cosio</p> <p>Atrial fibrillation as a consequence of left ventricular dysfunction. L. Kappenberger</p> <p>Left ventricular dysfunction as a consequence of atrial fibrillation S.M. Cobbe</p> <p>Anti-arrhythmic drugs: mechanisms and clinical implications in heart failure J. Clémenty</p> <p>The atrial fibrillation-cardiac heart failure trial D. Roy</p>	ORAL SESSIONS				POSTER SESSION 4
15:30									
COFFEE BREAK - MODERATED POSTERS SESSION									
16:30	<p>Controversies in cardiac resynchronisation therapy treatment Chairpersons: J. Clémenty, L. de Roy</p> <p>Value of cardiac resynchronisation therapy in right bundle branch block patients I. Fernandez Lozano</p> <p>Value of cardiac resynchronisation therapy in atrial fibrillation patients with narrow QRS and preserved systolic function M. Brignole</p> <p>Value of CRT in uncommon myocardial diseases F. Gadler</p> <p>Value of cardiac resynchronisation therapy after upgrading from a right ventricular pacing system S. Cazeau</p>	<p>Catheter ablation of unusual supraventricular arrhythmias Chairpersons: J.F.R. de Sousa, J. Kautzner</p> <p>Reentrant atrial tachycardias D. Shah</p> <p>Arrhythmias after atrial fibrillation ablation G. Hindricks</p> <p>Focal atrial tachycardias J. Hebe</p> <p>Unusual accessory pathways J.L. Merino Llorens</p>	<p>New tools for PV isolation: hope or hype? Chairpersons: M. Scanavacca, M. Allessie*</p> <p>Ultrasound balloon K.-H. Kuck</p> <p>Laser/Fiberoptic balloon S. Themistoklakis</p> <p>Cryo balloon N. Marrouche</p> <p>Radiofrequency balloon To be announced*</p>	<p>Arrhythmias in athletes Chairpersons: F. Furlanello, R. Hatala</p> <p>Which type of arrhythmias? J.L. Mont Girbau</p> <p>What is the mechanism? H. Heidbuchel</p> <p>How to screen them? A. Biffi</p> <p>How to prevent them? L. Boersma*</p>	ORAL SESSIONS				POSTER SESSION 4
18:00									
18:15 19:45	SATELLITE SYMPOSIA								

* Still to be confirmed at the date of printing (09 February 2005)

WEDNESDAY 29 JUNE 2005 - MORNING

	AUDITORIUM	ROOM 2.A	ROOM 1.B	ROOM 1.A	ROOM 0.A	ROOM 3.A	ROOM 2.B	ROOM 2.C	POSTER AREA
08:30	<p>Evidence in pacing Chairpersons: D.G. Benditt, D. Roy</p> <p>Mortality overview of large trials N. Freemantle*</p> <p>From guidelines to real life H. Ector</p> <p>Do sophisticated pacemakers reduce complications? M. Lunati*</p> <p>The pacemaker follow up in 2005 J.C. Nielsen</p>	<p>Is it justified to implant a cardiac resynchronisation therapy device without implantable cardioverter-defibrillator backup? Chairperson: G. Steinbeck</p> <p>Protagonist: J.C. Daubert Antagonist: A.J. Moss</p> <p>EP study should be performed in all implantable cardioverter-defibrillator candidates for primary prevention of sudden cardiac death Chairpersons: H.U. Klein</p> <p>Protagonist: J. Villacastin Antagonist: V. Dubrauský</p>	<p>Short QT syndrome: a new clinical entity Chairpersons: M. Borggreffe, H. Le Marec</p> <p>Diagnostic criteria I. Gussak</p> <p>Clinical presentation F. Gaita</p> <p>Genetic and ionic mechanisms R. Brugada Terradellas</p> <p>Management C. Wolpert</p>	<p>Conventional indications for catheter ablation Chairpersons: J. Farré, G. Breithardt</p> <p>Accessory pathways C. Lundqvist-Blomström</p> <p>AV nodal reentrant tachycardia R. Hatala</p> <p>Atrial flutter F. Garcia Cosio</p> <p>Ventricular tachycardia R. Peinado</p>	ORAL SESSIONS				
10:00	COFFEE BREAK								
11:00	<p>Guidelines Chairpersons: H.J. Wellens, L. Kappenberger</p> <p>Guidelines on atrial fibrillation H. Crijns</p> <p>Guidelines on SVT C. Blomström-Lundqvist</p> <p>Guidelines on HCMP W.J. McKenna</p> <p>Guidelines on Pacemaker therapy P.F. Vardas</p> <p>Guidelines on ventricular tachycardia M. Borggreffe</p> <p>Guidelines on sudden death S.G. Priori</p>	<p>Future cardiac resynchronisation therapy developments Chairpersons: M.J. Schalij, C. Butter</p> <p>Cardiac resynchronisation therapy device as multi-modality treatment and diagnostic platform E. Hoffman</p> <p>Implementing biological monitoring tools F.D. Murgatroyd*</p> <p>Lead technology B. Lüderitz</p> <p>Combining multiple device technologies in end stage heart failure H. Schmidinger</p>	<p>Prevention of sudden death in the community Chairpersons: M. Taborsky, P-E. Bloch Thompsen</p> <p>Epidemiology of sudden cardiac death R.W. Koster</p> <p>Automated external defibrillators in the community are part of the solution? E.N. Prystowsky</p> <p>Resuscitation by lay persons: is it effective? A. Capucci</p> <p>Is dissemination of in-house automated external defibrillators the optimal solution? M. Block</p>	<p>Management of the implantable cardioverter-defibrillator patient: tips and tricks Chairpersons: R.N.W. Hauer, A. Oto</p> <p>Optimising implantable cardioverter-defibrillator during follow-up M. Michels*</p> <p>Analysing complex implantable cardioverter-defibrillator tracings C. Kouakam</p> <p>Atrial arrhythmias: how to select and program the device? A. Quesada Dorador</p> <p>Management of lead complications C.E.H. Kennergren</p>	ORAL SESSIONS				
12:30	END OF MEETING								

* Still to be confirmed at the date of printing (09 February 2005)

RESYNCHRONIZING
RHYTHMS AND
SAVING LIVES



Allura[™]+HF CRT-D
Epic[™]+HF CRT-D



QuickSite[™]
Family of LV Leads



Apex[™] CS Introducer


**Faster, easier implantation for you.
Superior care for your patients.**

We kept these goals in mind when we designed the new St. Jude Medical CRT System. We've developed a seamlessly integrated system of delivery tools, leads and CRT devices that offer you and your patients the latest advances in implantation and therapy.

 ST. JUDE MEDICAL

www.sjm.com

Always use proper care of an implanted device from a trusted manufacturer. Always use the appropriate medical device for the patient. Always use the appropriate medical device for the patient. Always use the appropriate medical device for the patient.



Frontier[™] II CRT-P Device